3 unchanged sentences
Number Description
+Added: License, Development and Supply Agreement, dated as of March 2022, by and between Aquestive Therapeutics, Inc.
+Added: and Haisco Pharmaceutical Group Co., Ltd.
+Added: (filed herewith).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
10 unchanged sentences
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
+Added: 104 Cover Page Interactive Data File (formatted as Inline XBRL document and contained in exhibit 101)
+Added: + Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted.
+Added: The Company hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.
Table of Content
1 unchanged sentence
Aquestive Therapeutics, Inc.
−Removed: November 2, 2021 /s/ Keith J.
+Added: May 3, 2022 /s/ Keith J.
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 2, 2021 /s/ A.
+Added: May 3, 2022 /s/ A.
Ernest Toth, Jr.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.